Caplin Point Lab

Which are the latest news on Caplin Point Lab?

Why is Caplin Point Laboratories Ltd falling/rising?

As of 05-Sep, Caplin Point Laboratories Ltd's stock price is currently at 2,810.25, reflecting a short-term decline after a trend reversal, despite strong long-term performance with a year-to-date increase of 52.63%. The recent drop may be due to profit-taking as the stock approaches its 52-week high and concerns over its high valuation.

As of 05-Sep, Caplin Point Laboratories Ltd's stock price is falling, currently at 2,810.25, which reflects a decrease of 32.55 (-1.14%). This decline follows a trend reversal after four consecutive days of gains. The stock has underperformed its sector by 0.69% today and reached an intraday low of Rs 2,759.05, marking a drop of 2.95%. <BR><BR>Despite this short-term decline, the stock has shown strong performance over longer periods, with a year-to-date increase of 52.63% compared to a 10.21% decrease in the Sensex. Additionally, the stock has consistently outperformed the broader market over the past three years, with a remarkable 162.57% increase. <BR><BR>However, the current drop may be attributed to the stock trading close to its 52-week high, just 2.27% away from Rs 2,874, which could indicate profit-taking by investors. Furthermore, while there has been a significant increase in investor participation, with delivery volume rising by 196.92% against the 5-day average, the stock's valuation appears expensive with a Price to Book Value of 6, which may deter some investors. <BR><BR>Overall, while Caplin Point Laboratories Ltd has demonstrated strong historical performance and management efficiency, the recent price movement reflects a combination of profit-taking and concerns over its high valuation relative to peers.

Should I buy, sell or hold Caplin Point Laboratories Ltd?

Who are in the management team of Caplin Point Lab?

The management team of Caplin Point Lab includes C C Paarthipan (Chairman), D Sathyanarayanan, C K Gariyali, Deenadayalan Singaram, and R Nagendran (all Independent Directors), along with Sridhar Ganesan (Non-Independent Executive Director).

The management team of Caplin Point Lab includes the following members:<BR><BR>1. C C Paarthipan - Chairman & Non-Executive Director<BR>2. D Sathyanarayanan - Independent Non-Executive Director<BR>3. C K Gariyali - Independent Director<BR>4. Deenadayalan Singaram - Independent Non-Executive Director<BR>5. R Nagendran - Independent Non-Executive Director<BR>6. Sridhar Ganesan - Non-Independent Executive Director<BR><BR>If you need more details about their roles or contributions, feel free to ask!

What does Caplin Point Lab do?

Caplin Point Laboratories Ltd is a fully integrated pharmaceutical company that develops, produces, and markets generic and branded products. As of June 2026, it reported net sales of 610 Cr and a net profit of 177 Cr, with a market cap of INR 19,122 Cr.

Overview:<BR>Caplin Point Laboratories Ltd is a fully integrated pharmaceutical company engaged in the production, development, and marketing of a wide range of generic formulations and branded products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap.<BR><BR>History:<BR>Incorporated on April 16th, 1990, Caplin Point Laboratories has maintained its status as a fully integrated pharma company. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 610 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 177 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 19,122 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 29.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.28%<BR>- Debt Equity: -0.28<BR>- Return on Equity: 17.88%<BR>- Price to Book: 5.36<BR><BR>Contact Details:<BR>Address: Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estate Chennai Tamil Nadu : 600096<BR>Tel: 91-44-24968000/71148000/28156653<BR>Email: investor@caplinpoint.net/info@capli<BR>Website: http://www.caplinpoint.net

Who are the peers of the Caplin Point Lab?

Caplin Point Lab's peers include Neuland Labs, Piramal Pharma, Acutaas Chemical, Pfizer, Granules India, ERIS Lifescience, Astrazeneca Pharma, OneSource Specialty, Shilpa Medicare, and Cohance Life. Management risk varies from excellent to below average among these companies, with Acutaas Chemical showing the highest 1-year return at 124.38%, while Caplin Point Lab has a 1-year return of 19.80%.

Peers: The peers of Caplin Point Lab are Neuland Labs., Piramal Pharma, Acutaas Chemical, Pfizer, Granules India, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Shilpa Medicare, and Cohance Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Neuland Labs., Acutaas Chemical, and Astrazeneca Phar, while Good management risk is found at Caplin Point Lab, Pfizer, Granules India, ERIS Lifescience, and Shilpa Medicare. Average management risk is seen at Piramal Pharma and Cohance Life, while Below Average management risk is noted at OneSource Speci. Growth is Excellent for Neuland Labs. and Acutaas Chemical, while Good growth is found at Shilpa Medicare. Caplin Point Lab, Pfizer, Granules India, ERIS Lifescience, and Cohance Life exhibit Below Average growth, while Average growth is noted at Astrazeneca Phar and OneSource Speci. Finally, Below Average growth is seen at Piramal Pharma. Excellent capital structure is observed at Neuland Labs., Acutaas Chemical, Pfizer, Granules India, and Astrazeneca Phar, while Good capital structure is found at ERIS Lifescience. Caplin Point Lab has an Excellent capital structure, while Average capital structure is noted at Piramal Pharma and Cohance Life, and Below Average capital structure is seen at OneSource Speci. and Shilpa Medicare.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 124.38%, while ERIS Lifescience has the lowest at -27.88%. Caplin Point Lab's 1-year return of 19.80% is significantly higher than ERIS Lifescience but lower than Acutaas Chemical. Additionally, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., and Cohance Life have negative six-month returns.

How big is Caplin Point Lab?

As of 31st August, Caplin Point Laboratories Ltd has a market capitalization of 19,122.00 Cr, with recent net sales of 2,287.33 Cr and a net profit of 665.35 Cr.

As of 31st August, Caplin Point Laboratories Ltd has a market capitalization of 19,122.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,287.33 Cr and a Net Profit of 665.35 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,850.49 Cr and Total Assets totaling 3,205.62 Cr.

Has Caplin Point Laboratories Ltd declared dividend?

Yes, Caplin Point Laboratories Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of September 18, 2026. The company has demonstrated strong total returns across various periods, highlighting a positive outlook for investors.

Caplin Point Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4 per share<BR>- Ex-date: 18 Sep 26<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was 23.0%, the dividend return was 0.40%, leading to a total return of 23.4%.<BR><BR>In the 6 Months period, the price return was 43.61%, the dividend return was 0.47%, resulting in a total return of 44.08%.<BR><BR>In the 1 Year period, the price return was 16.62%, the dividend return was 0.52%, culminating in a total return of 17.14%.<BR><BR>In the 2 Years period, the price return was 59.55%, the dividend return was 0.90%, which brought the total return to 60.45%.<BR><BR>In the 3 Years period, the price return was 145.6%, the dividend return was 2.00%, leading to a total return of 147.6%.<BR><BR>In the 4 Years period, the price return was 213.7%, the dividend return was 3.29%, resulting in a total return of 216.99%.<BR><BR>In the 5 Years period, the price return was 192.9%, the dividend return was 3.11%, culminating in a total return of 196.01%.<BR><BR>Overall, Caplin Point Laboratories Ltd has shown a strong performance with significant total returns across various periods, alongside a substantial dividend declaration, indicating a positive outlook for investors.

When is the next results date for Caplin Point Laboratories Ltd?

The next results date for Caplin Point Laboratories Ltd is 12 August 2026.

The next results date for Caplin Point Laboratories Ltd is scheduled for 12 August 2026.

Are Caplin Point Laboratories Ltd latest results good or bad?

Caplin Point Laboratories Ltd's latest Q4 FY26 results are generally positive, with a net profit of ₹170.11 crores and revenue of ₹600.16 crores, both showing significant year-on-year growth. However, a decline in operating margin raises some concerns, and while the market reacted favorably, investors should be cautious about potential margin pressures.

Caplin Point Laboratories Ltd's latest results for Q4 FY26 can be considered good overall. The company reported a net profit of ₹170.11 crores, which is a 3.80% increase quarter-on-quarter and a significant 19.32% increase year-on-year. Revenue also showed strong growth, reaching ₹600.16 crores, up 10.57% from the previous quarter and 19.45% compared to the same quarter last year.<BR><BR>However, there are some concerns regarding the operating margin, which declined to 34.03% from 34.95% in the previous quarter, indicating some pressure on operational efficiency. Despite this, the overall financial performance reflects a positive trend, with record highs in revenue and profit levels.<BR><BR>The market reacted positively to these results, with the stock price jumping nearly 10% following the announcement. While the company has strong fundamentals, the valuation appears stretched, and investors should remain cautious about potential margin pressures moving forward. Overall, the results indicate a strong financial trajectory, but ongoing monitoring of margin dynamics will be important.

Is Caplin Point Lab technically bullish or bearish?

As of November 27, 2025, Caplin Point Lab's technical trend has shifted to bearish, driven by negative indicators such as a bearish MACD and moving averages, despite some bullish signals in the monthly OBV.

As of 27 November 2025, the technical trend for Caplin Point Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. The Dow Theory also indicates a mildly bearish trend on the weekly and monthly time frames. Despite some bullish signals in the monthly OBV, the overall technical picture remains negative.

How has been the historical performance of Caplin Point Lab?

Caplin Point Lab has shown consistent growth, with net sales increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25, alongside improvements in operating profit, profit before tax, and total assets. Overall, the company's financial performance indicates a strong upward trend across key metrics.

Answer:<BR>The historical performance of Caplin Point Lab shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Caplin Point Lab has demonstrated significant growth in net sales, increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. The company's operating profit (PBDIT) has similarly improved, reaching 743.36 Cr in Mar'25, up from 250.37 Cr in Mar'19. Profit before tax has followed suit, climbing from 226.88 Cr in Mar'19 to 676.79 Cr in Mar'25, while profit after tax increased from 176.56 Cr to 541.10 Cr over the same period. The company's total assets have expanded from 1,125.76 Cr in Mar'20 to 3,205.62 Cr in Mar'25, indicating robust asset growth. Shareholder's funds have also risen significantly, from 947.91 Cr in Mar'20 to 2,850.49 Cr in Mar'25. Cash flow from operating activities has improved, reaching 432.00 Cr in Mar'25, compared to 44.00 Cr in Mar'20, while net cash inflow turned positive at 60.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Caplin Point Lab's financial performance reflects a strong upward trend across various metrics, indicating a healthy and growing business.

Is Caplin Point Lab overvalued or undervalued?

As of June 8, 2023, Caplin Point Lab is considered very expensive and overvalued with a PE ratio of 29.63 and an EV to EBITDA of 23.18, especially when compared to peers like Cipla and Sun Pharma, and has recently declined by 4.29% while the Sensex increased by 1.43%.

As of 8 June 2023, the valuation grade for Caplin Point Lab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 29.63, an EV to EBITDA of 23.18, and a PEG ratio of 1.72, all suggesting a premium valuation compared to its earnings and growth potential.<BR><BR>In comparison with peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla presents a more attractive valuation with a PE of 22.99 and an EV to EBITDA of 15.93. The recent performance of Caplin Point Lab shows a 1-week decline of 4.29%, contrasting with a 1.43% increase in the Sensex, further reinforcing the notion of overvaluation in the current market environment.

Who are the top shareholders of the Caplin Point Lab?

The top shareholders of Caplin Point Lab include promoter P Vijayalakshmi with 24.71%, 17 mutual fund schemes holding 1.74%, 139 foreign institutional investors with 5.73%, and individual investors owning 15.11%. The highest public shareholder is Uti Small Cap Fund at 1.27%.

The top shareholders of Caplin Point Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is P Vijayalakshmi, who owns 24.71% of the company. Additionally, there are 17 mutual fund schemes that collectively hold 1.74%, and 139 foreign institutional investors (FIIs) with a combined holding of 5.73%. The highest public shareholder is Uti Small Cap Fund, which holds 1.27%. Individual investors also have a significant presence, holding 15.11% of the shares.